Trends in Immunotherapy (IO) Use and Survival Among Patients With High‐Incidence Stage IV Cancers Across the United States
Journal of Surgical Oncology · 2025-06 · 131 (7) · 1455-1466
DOI: 10.1002/jso.28084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 13.01.2025. Verfasst von Samantha C Warwar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, This work is supported by the National Institutes of Health training..
Abstract (Originalsprache)
Background and Objectives IO has transformed cancer management, but its adoption in advanced cancer patients varies by tumor type. With more Stage IV patients undergoing surgery, understanding site‐specific outcomes in these challenging patients is essential. We aimed to evaluate IO use and survival trends for Stage IV cancer patients across high‐incidence cancers in the US.
Methods
Patients diagnosed with Stage IV prostate, breast, melanoma, colorectal, renal, bladder, lung, or pancreas cancer were identified from the National Cancer Database (2004–2020). Cochrane–Armitage test and Kaplan–Meier methods assessed IO and overall survival across three periods: 2004–2010, 2011–2015, and 2016–2020.
Results
Among 1 425 731 Stage IV cancer patients, most had lung (50.0%), pancreas (12.5%), and breast cancer (9.3%), while the least had melanoma (2.2%). From periods 1 to 3, IO use increased from 1.0% to 24.6%, notably in melanoma (9.5% to 58.5%, p < 0.001). Melanoma exhibited the greatest survival gains (median survival: 7.1 to 14.9 months). Absolute increases in 3‐year overall survival rates ranged from 3.4% in pancreas (1.7% to 5.1%) to 21.4% in melanoma (15.7% to 37.1%).
Conclusions
Utilization of IO is tumor‐site specific and associated with improved survival rates for Stage IV cancer, with varied success across types. Variations in receipt highlight ongoing challenges to ensure equitable adoption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Northwestern Quality Improvement, Research, & Education in Surgery (NQUIRES), Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
ORCID-Profile: David J Bentrem
Förderung
- NCI NIH HHS
- This work is supported by the National Institutes of Health training.
Zitieren
APA
Warwar, S. C., Janczewski, L. M., Rodriguez, G. M., Wayne, J. D., & Bentrem, D. J. (2025). Trends in Immunotherapy (IO) Use and Survival Among Patients With High‐Incidence Stage IV Cancers Across the United States. Journal of Surgical Oncology, 131(7), 1455-1466. https://doi.org/10.1002/jso.28084
Vancouver
Warwar SC, Janczewski LM, Rodriguez GM, Wayne JD, Bentrem DJ. Trends in Immunotherapy (IO) Use and Survival Among Patients With High‐Incidence Stage IV Cancers Across the United States. Journal of Surgical Oncology. 2025;131(7):1455-1466. doi:10.1002/jso.28084
BibTeX
@article{Warwar2025,
author = {Warwar, Samantha C and Janczewski, Lauren M and Rodriguez, Gladys M and Wayne, Jeffrey D and Bentrem, David J},
title = {Trends in Immunotherapy (IO) Use and Survival Among Patients With High‐Incidence Stage IV Cancers Across the United States},
journal = {Journal of Surgical Oncology},
year = {2025},
volume = {131},
number = {7},
pages = {1455--1466},
doi = {10.1002/jso.28084}
}
EUVIMED